儿童肥胖的药物治疗：现状和未来前景。
Pharmacotherapy for childhood obesity: present and future prospects.
机构信息
Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1103, USA.
出版信息
Int J Obes (Lond). 2013 Jan;37(1):1-15. doi: 10.1038/ijo.2012.144. Epub 2012 Aug 28.
Abstract
Pediatric obesity is a serious medical condition associated with significant comorbidities during childhood and adulthood. Lifestyle modifications are essential for treating children with obesity, yet many have insufficient response to improve health with behavioral approaches alone. This review summarizes the relatively sparse data on pharmacotherapy for pediatric obesity and presents information on obesity medications in development. Most previously studied medications demonstrated, at best, modest effects on body weight and obesity-related conditions. It is to be hoped that the future will bring new drugs targeting specific obesity phenotypes that will allow clinicians to use etiology-specific, and therefore more effective, anti-obesity therapies.
摘要
儿科肥胖症是一种严重的医学病症，与儿童期和成年期的多种并发症相关。生活方式的改变对于治疗肥胖儿童至关重要，但许多儿童仅通过行为方法改善健康的反应不足。本综述总结了儿科肥胖症药物治疗的相对较少的数据，并介绍了正在开发中的肥胖症药物信息。大多数先前研究的药物最多只能对体重和肥胖相关疾病产生适度的影响。人们希望未来能开发出针对特定肥胖表型的新药，使临床医生能够使用病因特异性、因此更有效的抗肥胖疗法。
相似文献
1
Pharmacotherapy for childhood obesity: present and future prospects.儿童肥胖的药物治疗：现状和未来前景。
Int J Obes (Lond). 2013 Jan;37(1):1-15. doi: 10.1038/ijo.2012.144. Epub 2012 Aug 28.
2
[The pharmacotherapy of obesity].[肥胖症的药物治疗]
Acta Pharm Hung. 2015;85(1):3-17.
3
Pharmacological approaches for the treatment of obesity.治疗肥胖症的药理学方法。
Drugs. 2002;62(6):915-44. doi: 10.2165/00003495-200262060-00005.
4
Drug strategies for the treatment of obesity.治疗肥胖症的药物策略。
IDrugs. 2003 Jun;6(6):566-72.
5
Current pharmacotherapy for obesity.肥胖的当前药物治疗。
Nat Rev Endocrinol. 2018 Jan;14(1):12-24. doi: 10.1038/nrendo.2017.122. Epub 2017 Oct 13.
6
Pharmacotherapy of obesity: an update.肥胖症的药物治疗：最新进展
Nutr Clin Care. 2003 Jan-Apr;6(1):27-37.
7
Antiobesity effects of green tea catechins: a mechanistic review.绿茶儿茶素的抗肥胖作用：机制综述。
J Nutr Biochem. 2011 Jan;22(1):1-7. doi: 10.1016/j.jnutbio.2010.06.006. Epub 2010 Nov 5.
8
Pharmacotherapy for obesity.肥胖症的药物治疗
Aust Fam Physician. 2017;46(7):472-477.
9
Pharmacotherapy of obesity: targets and perspectives.肥胖症的药物治疗：靶点与展望
Trends Pharmacol Sci. 2001 May;22(5):247-54. doi: 10.1016/s0165-6147(00)01664-3.
10
[Pharmacological therapy of obesity].[肥胖症的药物治疗]
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
引用本文的文献
1
Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians.儿童肥胖症治疗：糖尿病教育工作者和临床医生的考量因素
Diabetes Spectr. 2024 Nov 15;37(4):313-324. doi: 10.2337/dsi24-0005. eCollection 2024 Fall.
2
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.胰高血糖素样肽-1受体激动剂在无糖尿病超重/肥胖青少年中的抗肥胖作用及安全性：一项系统评价和荟萃分析。
Cureus. 2024 Aug 6;16(8):e66280. doi: 10.7759/cureus.66280. eCollection 2024 Aug.
3
Causes, Consequences, and Preventive Strategies for Childhood Obesity: A Narrative Review.儿童肥胖的成因、后果及预防策略：一项叙述性综述
Cureus. 2024 Jul 20;16(7):e64985. doi: 10.7759/cureus.64985. eCollection 2024 Jul.
4
Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022.药物性体重增加与超重和肥胖儿童的先进治疗方法：肥胖医学协会（OMA）2022年临床实践声明
Obes Pillars. 2022 Dec 5;4:100048. doi: 10.1016/j.obpill.2022.100048. eCollection 2022 Dec.
5
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.调节能量平衡以对抗肥胖的药理学策略的最新进展。
RSC Med Chem. 2023 Jun 14;14(8):1429-1445. doi: 10.1039/d3md00107e. eCollection 2023 Aug 16.
6
Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.利拉鲁肽治疗儿童和青少年肥胖的疗效：随机对照试验的系统评价和荟萃分析
Children (Basel). 2023 Jan 25;10(2):208. doi: 10.3390/children10020208.
7
The anorexic effect of DL-fenfluramine is dependent on animals' habituation to different food types.右旋芬氟拉明的厌食作用取决于动物对不同食物类型的适应性。
Front Integr Neurosci. 2022 Nov 16;16:1010181. doi: 10.3389/fnint.2022.1010181. eCollection 2022.
8
Signaling pathways in obesity: mechanisms and therapeutic interventions.肥胖症中的信号通路：机制与治疗干预。
Signal Transduct Target Ther. 2022 Aug 28;7(1):298. doi: 10.1038/s41392-022-01149-x.
9
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits.新的抗肥胖疗法有望通过对肥胖遗传特征的了解而出现。
Nat Rev Endocrinol. 2022 Oct;18(10):623-637. doi: 10.1038/s41574-022-00716-0. Epub 2022 Jul 28.
10
Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management.姜黄素类化合物用于代谢综合征：个性化预防和治疗管理的荟萃分析证据
Front Nutr. 2022 Jun 9;9:891339. doi: 10.3389/fnut.2022.891339. eCollection 2022.
本文引用的文献
1
FDA approves Belviq to treat some overweight or obese adults.美国食品药品监督管理局批准Belviq用于治疗某些超重或肥胖的成年人。
Home Healthc Nurse. 2012 Sep;30(8):443-4.
2
Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression.肝胰岛素信号对于肥胖依赖性 SREBP-1c mRNA 的表达是必需的，但对于摄食依赖性表达不是必需的。
Cell Metab. 2012 Jun 6;15(6):873-84. doi: 10.1016/j.cmet.2012.05.002.
3
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.BLOOM-DM 研究：用于治疗 2 型糖尿病患者体重的乐卡司汀随机安慰剂对照临床试验。
Obesity (Silver Spring). 2012 Jul;20(7):1426-36. doi: 10.1038/oby.2012.66. Epub 2012 Mar 16.
4
Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010.美国儿童和青少年肥胖率及体重指数趋势，1999-2010 年。
JAMA. 2012 Feb 1;307(5):483-90. doi: 10.1001/jama.2012.40. Epub 2012 Jan 17.
5
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.达格列净对二甲双胍血糖控制不佳的 2 型糖尿病患者体重、总脂肪量和局部脂肪组织分布的影响。
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.
6
Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999-2006.与二甲双胍治疗和维生素 B₁₂ 补充相关的生化 B₁₂ 缺乏症：1999-2006 年全国健康与营养调查。
Diabetes Care. 2012 Feb;35(2):327-33. doi: 10.2337/dc11-1582. Epub 2011 Dec 16.
7
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.为期两年的肥胖和超重成年人用控释苯丁胺/托吡酯持续减肥和代谢获益（SEQUEL）：一项随机、安慰剂对照、3 期扩展研究。
Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7.
8
Childhood adiposity, adult adiposity, and cardiovascular risk factors.儿童期肥胖、成年期肥胖与心血管危险因素。
N Engl J Med. 2011 Nov 17;365(20):1876-85. doi: 10.1056/NEJMoa1010112.
9
Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.儿童和青少年心血管健康与风险降低综合指南专家小组：总结报告
Pediatrics. 2011 Dec;128 Suppl 5(Suppl 5):S213-56. doi: 10.1542/peds.2009-2107C. Epub 2011 Nov 14.
10
Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.阿卡波糖与格列本脲对二甲双胍控制不佳的 2 型糖尿病患者血糖波动及氧化应激的影响：一项 24 周、随机、开放、平行分组比较研究。
Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.
Zotero 插件